Search

Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Janssen, Merck, Roche, Takeda Research funding: AbbVie, AstraZeneca, BeiGene, CSL Behring, Gilead. ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAïVE (TN) CLL/SLL: EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY B Introduction: b Zanu, a next-generation Bruton tyrosine kinase inhibitor (BTKi), demonstrated superior progression-free survival (PFS) by independent review versus BR in pts with TN CLL/SLL without (w/o) del(17p) in the SEQUOIA study (NCT03336333) at a median follow-up of 26.2 mo; pts with del(17p) treated with zanu in a separate cohort had similar outcomes to pts w/o del(17p). [Extracted from the article]

Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Modern oral inhibitors of B-cell receptor signalling pathways such as ibrutinib and idealise and the bcl-2 inhibitor venetoclax represent effective treatment options in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL). Richter´s transformation (RT, progression of CLL to aggressive lymphoproliferation, most commonly diffuse large B-cell lymphoma, DLBCL) is usually a prognostically highly adverse event with limited treatment options and very short survival, especially when RT occurs on treatment with one of the new inhibitors. We present a case report of RT developing in a 58-year-old CLL patient who relapsed following allogeneic stem cell transplantation treated with ibrutinib. After 11 months on ibrutinib therapy, the patient experienced progression in the form of massive intraabdominal lymphadenopathy. Positron emission tomography/computed tomography (PET/CT) revealed significant hypermetabolism of glucose in the abdominal mass. A needle biopsy was performed and histology confirmed DLBCL. The patient was treated with R-CHOP chemoimmunotherapy and subsequently with R-GD (rituximab, gemcitabine, dexamethasone) because of R-CHOP resistance. However, active anti-lymphoma therapy had to be terminated because of severe thrombocytopenia. The therapeutic approach was changed to symptom management and the patient died in a hospice 2.5 months after diagnosis of RT. In conclusion, this case report demonstrates the extremely unfavourable prognosis of Richter´s syndrome arising on ibrutinib therapy in a patient with advanced CLL. [ABSTRACT FROM AUTHOR]

Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Introduction Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients (pts) with malignant tumors. Increased risk of VTE is well described in a variety of hematologic malignancies; however, data regarding VTE in chronic lymphocytic leukemia (CLL) is very limited. Patients and methods: We retrospectively analyzed clinical and laboratory data of 346 consecutive pts with CLL followed up at 4th Department of Internal Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic, diagnosed between 1999 and 2011 (males, 64%; median age, 64 years; low/intermediate/high Rai modified risk in 41/47/12%). Results: After a median follow-up of 72 months (range, 26-138), at least one episode of VTE occurred in 38 patients (11%). VTE developed after a median of 34 months from CLL diagnosis. Incidence of VTE was 1.67% per patient year of follow-up. There was a high proportion of unfavourable prognostic factors (advanced Rai stages, unmutated IgVH genes, unfavourable cytogenetics) in pts with VTE. The presence of 0/1/2/3 additional risk factors for VTE was identified in 2/16/14/6 patients. The most common risk factors for VTE besides age (n = 24) were corticosteroid therapy (n = 13), other malignancies (n = 9) and obesity (n = 7). Recurrence of VTE was diagnosed in 7 pts. Performance status ≥ 2 and inherited thrombophilia were significant risk factors for VTE development in univariate and multivariate analysis. VTE was not associated with shorter overall survival. Conclusion: Based on our results, VTE is a relatively frequent complication in patients with CLL. Although most patients had other known risk factors for VTE including CLL treatment, 29% had no risk factors or only age ≥ 60 years. These findings demonstrate the possible role of CLL in the development of VTE. [ABSTRACT FROM AUTHOR]

The rate of the45Ca2+ uptake by the submerged Trichoderma viride mycelium increased with the age of the culture from 6 h until a maximum which was reached at about 30 h, and then decreased until the uptake was virtually zero. The decrease in the rate of the45Ca2+ uptake was accompanied by an increase of mycelial mass. The uptake rate could not be reactivated upon substituting the medium for a fresh one, without or with dilution of the mycelium. The results suggest that the rate of45Ca2+ uptake reflects the biological age of the submerged culture. The surface-cultivated mycelium took up45Ca2+ proportionally with time. The autoradiography of colonies showed that45Ca2+ was distributed homogeneously throughout the mycelium during vegetative growth while conidiation was accompanied by a massive accumulation of45Ca2+ in conidia. [ABSTRACT FROM AUTHOR]

Abstract: The interaction of a copper complexes containing Schiff bases with calf thymus (CT) DNA was investigated by spectroscopic methods. UV–vis, fluorescence and CD spectroscopies were conducted to assess their binding ability with CT DNA. The binding constants K have been estimated from 0.8 to 9.1×104 M−1. The percentage of hypochromism is found to be over 70% (from spectral titrations). The results showed that the copper(II) complexes could bind to DNA with an intercalative mode. Synergic action of Cu(II) complexes with ascorbic acid against Candida albicans induced the generation of free radicals and increased (more than 60 times) antimicrobial effect of these complexes. [Copyright &y& Elsevier]